Company intelligence / Profile preview

BCP09

Wuxi, Jiangsu, China

Ownership: Private
Employees: ~150
Development stage: Other

Overview

BioCity Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and nephrology. The company's lead candidate, BCP09 (also known as SC0062), is a highly selective endothelin A receptor antagonist currently being evaluated for the treatment of chronic kidney diseases, including diabetic nephropathy and IgA nephropathy. Beyond its nephrology portfolio, BioCity is advancing a robust pipeline of immuno-oncology agents, including next-generation CD47 antibodies and adenosine receptor antagonists. The company leverages its internal R&D capabilities to address significant unmet medical needs through precision medicine and targeted therapies.

Therapeutic areas: OncologyNephrology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

AstraZeneca

Beyond the preview

Go deeper on BCP09.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCP09.

Explore the full profile